Skip to main content
. 2022 Mar 15;8(3):e32831. doi: 10.2196/32831

Table 3.

Bivariate analysis of factors associated with COVID-19 severity and mortality.

Variable Severity Mortality

Mild-moderate, n (%) Severe-critical, n (%) P value Survivors, n (%) Deaths, n (%) P value
Sex .45

.005

Male 1318 (49.9) 1323 (50.1)
2132 (80.7) 509 (19.3)

Female 767 (51.1) 733 (48.9)
1263 (84.2) 237 (15.8)
Age (years) <.001

<.001

<40 849 (71.2) 344 (28.8)
1115 (93.5) 78 (6.5)

40-59 779 (49.6) 792 (50.4)
1334 (84.9) 237 (15.1)

≥60 457 (33.2) 920 (66.8)
946 (68.7) 431 (31.3)
Working in health care setting <.001

<.001

Non–health care workers 1965 (49.2) 2029 (50.8)
3254 (81.5) 740 (18.5)

Health care workers 120 (81.6) 27 (18.4)
141 (95.9) 6 (4.1)
Positive history of contact with patient with COVID-19 1116 (66.0) 574 (34.0) <.001 1456 (86.2) 234 (13.8) <.001
Smoking <.001

.29

Ever 228 (37.7) 376 (62.3)
486 (80.5) 118 (19.5)

Never 1857 (52.5) 1680 (47.5)
2909 (82.2) 628 (17.8)
Comorbidities 592 (34.2) 1141 (65.8) <.001 1237 (71.4) 496 (28.6) <.001

Hypertension 353 (34.6) 668 (65.4) <.001 714 (69.9) 307 (30.1) <.001

Diabetes mellitus 319 (34.0) 620 (66.0) <.001 650 (69.2) 289 (30.8) <.001

Heart diseases 91 (30.0) 212 (70.0) <.001 190 (62.7) 113 (37.3) <.001

Renal disease 25 (17.9) 115 (82.1) <.001 108 (77.1) 32 (22.9) .13

Asthma 50 (45.0) 61 (55.0) .26 91 (82.0) 20 (18.0) >.99

Respiratory diseases 21 (34.4) 40 (65.6) .01 38 (62.3) 23 (37.7) <.001

Malignancy 21 (33.9) 41 (66.1) .009 43 (69.4) 19 (30.6) .009

Immunocompromising conditions 12 (26.7) 33 (73.3) .001 39 (86.7) 6 (13.3) .41

Liver disease 8 (36.4) 14 (63.6) .19 16 (72.7) 6 (27.3) .26

Tuberculosis 19 (33.9) 37 (66.1) .01 42 (75.0) 14 (25.0) .17

Cerebrovascular disease 8 (42.1) 11 (57.9) .47 12 (63.2) 7 (36.8) .03